Or2l13 agonists to treat cvd with dysregulated platelet activation
AssigneeThe Cleveland Clinic Foundation
InventorsShaun Stauffer, Scott Cameron, Vara Prasad Josyula
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions, systems, and methods for treating a subject with, or elevated risk for, a cardiovascular disease (CVD) involving dysregulated platelet activation comprising: treating the subject with a composition comprising an OR2L13 activating agent (e.g., carvone; 2-tert-Butyl-4-Methylphenol; or 2-tert-Butyl-5-Methylphenol). In certain embodiments, the CVD comprises abdominal aortic aneurysm (AAA) or thrombosis.
Claims21
A method of treating a subject with, or elevated risk for, a cardiovascular disease (CVD) involving dysregulated platelet activation comprising:
- treating a subject with a composition comprising an OR2L13 activating agent;
- wherein said subject has, or is at elevated risk for, a CVD involving dysregulated platelet activation;
- and
- optionally, wherein said OR2L13 activating agent comprises:
- 2-tert-Butyl-4-Methylphenol or 2-tert-Butyl-5-Methylphenol.
A composition comprising:
- a) a blood or plasma sample from a subject that has, or is at elevated risk for, a CVD involving dysregulated platelet activation;
- and
- b) a composition comprising an OR2L13 activating agent, and optionally, wherein said OR2L13 activating agent comprises:
- 2-tert-Butyl-4-Methylphenol or 2-tert-Butyl-5-Methylphenol.
21-24. (canceled)
Dependencies are inferred from the claim text.